Holen Sie sich die Stockscreener-App
4.52
11.60%
0.47
Handel nachbörslich:
4.47
-0.05
-1.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MNKD?
Forum
Prognose
Aktiensplit
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
5 Best Rising Penny Stocks to Buy According to Wall Street Analysts - Insider Monkey
Is MannKind Corporation (MNKD) A Good Stock To Buy Now? - Yahoo Finance
MannKind Corp (MNKD) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
MannKind shares, Friday focus on the U.S. listing - AD HOC NEWS
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Breakthrough T1D backs MannKind’s pediatric Afrezza trial - Stock Titan
MNKD Stock Price, Quote & Chart - ChartMill
MannKind Corp (MNKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MannKind Corp (MNKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MannKind Corp (MNKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MannKind Corp (MNKD) Institutional Confidence - TradingKey
MannKind Corp (MNKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MannKind Corp (MNKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q1 2026 MannKind Corp Earnings Call Transcript - GuruFocus
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” - Insider Monkey
MANNKIND CORP (MNKD) Stock Chart - ChartMill
7 Hidden Penny Stocks to Invest In - Insider Monkey
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Yahoo Finance
ADA 2026 data highlight pediatric outcomes and treatment satisfaction with Afrezza - Contemporary Pediatrics
MannKind (MNKD) Stock Price, News & Analysis - MarketBeat
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Jim Cramer Says He Blessed MannKind as a Speculation Only - Insider Monkey
MannKind highlights wider role for Afrezza at ADA 2026 - The Pharma Letter
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends - Sahm
Jim Cramer Highlighted 16 Stocks Including Quantinuum, and the Market’s Appetite for New Supply - Insider Monkey
MannKind shares more data backing inhaled insulin - Drug Delivery Business
New data affirm safety and efficacy of MannKind's Afrezza inhaled insulin for children and adults with diabetes. - Pluang
MannKind Corporation Presents New Clinical Data Supporting Afrezza and FUROSCIX at ADA 2026 Scientific Sessions - Quiver Quantitative
Inhaled insulin data explore options for kids, pregnancy and pump users - Stock Titan
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy - Insider Monkey
MannKind Corp stock (US5638651064): focus on valuation metrics after recent FDA and partnership news - AD HOC NEWS
Earnings call transcript: MannKind Q1 2026 sees revenue growth, stock surges - Investing.com
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
Assessing MannKind (MNKD) Valuation After Recent Share Price Momentum And Royalty Growth Expectations - simplywall.st
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
MannKind Q1 2026 slides: revenue up 15%, three catalysts ahead - Investing.com
MannKind stock surges on United Therapeutics partnership deal - Investing.com
5 Most Promising Penny Stocks According to Wall Street Analysts - Insider Monkey
MannKind (MNKD) Announces Milestones in Nintedanib DPI Development for IPF - GuruFocus
MannKind (MNKD) Announces Milestones in Nintedanib DPI Developme - GuruFocus
MannKind completes patient enrollment in nintedanib DPI trials - Investing.com
MannKind Corporation Advances Nintedanib DPI Program for IPF with Phase 1b INFLO-1 Study Data Expected in Q3 2026 - Quiver Quantitative
MannKind tests inhaled IPF drug in global trial, first data Q3 2026 - Stock Titan
FDA approves MannKind’s Afrezza inhaled insulin for children with diabetes - Investing.com
FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older - Stock Titan
MannKind At An Inflection Point: Pediatric Expansion Drives The Story (NASDAQ:MNKD) - Seeking Alpha
MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw foc - AD HOC NEWS
Implications of Pediatric Inhaled Insulin Approval - PharmTech.com
MNKD stock eyes best month since 2022 ahead of FDA decision on pediatric diabetes treatment - MSN
symbol__ Stock Quote Price and Forecast - CNN
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market - Barchart.com
FDA approves Afrezza for children and adolescents with diabetes - Managed Healthcare Executive
3.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):